In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
Identifieur interne : 000E68 ( Main/Exploration ); précédent : 000E67; suivant : 000E69In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
Auteurs : Katrina Sleeman [États-Unis] ; Vasiliy P. Mishin ; Varough M. Deyde ; Yousuke Furuta ; Alexander I. Klimov ; Larisa V. GubarevaSource :
- Antimicrobial agents and chemotherapy [ 1098-6596 ] ; 2010.
Descripteurs français
- KwdFr :
- Amides (pharmacologie), Animaux, Antiviraux (pharmacologie), Chiens, Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Humains, Lignée cellulaire, Méthode des plages virales, Pyrazines (pharmacologie), Réplication virale (), Résistance virale aux médicaments, Sous-type H1N1 du virus de la grippe A (), Sous-type H1N1 du virus de la grippe A (physiologie), Sous-type H2N2 du virus de la grippe A (), Sous-type H2N2 du virus de la grippe A (physiologie), Sous-type H5N1 du virus de la grippe A (), Sous-type H5N1 du virus de la grippe A (physiologie), Suidae, Techniques in vitro, Tests de sensibilité microbienne, Virus de la grippe A (), Virus de la grippe A (physiologie), Virus influenza B (), Virus influenza B (physiologie).
- MESH :
- pharmacologie : Amides, Antiviraux, Pyrazines.
- physiologie : Sous-type H1N1 du virus de la grippe A, Sous-type H2N2 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A, Virus de la grippe A, Virus influenza B.
- traitement médicamenteux : Grippe humaine.
- virologie : Grippe humaine.
- Animaux, Chiens, Humains, Lignée cellulaire, Méthode des plages virales, Réplication virale, Résistance virale aux médicaments, Sous-type H1N1 du virus de la grippe A, Sous-type H2N2 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A, Suidae, Techniques in vitro, Tests de sensibilité microbienne, Virus de la grippe A, Virus influenza B.
English descriptors
- KwdEn :
- Amides (pharmacology), Animals, Antiviral Agents (pharmacology), Cell Line, Dogs, Drug Resistance, Viral, Humans, In Vitro Techniques, Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (physiology), Influenza A Virus, H2N2 Subtype (drug effects), Influenza A Virus, H2N2 Subtype (physiology), Influenza A Virus, H5N1 Subtype (drug effects), Influenza A Virus, H5N1 Subtype (physiology), Influenza A virus (drug effects), Influenza A virus (physiology), Influenza B virus (drug effects), Influenza B virus (physiology), Influenza, Human (drug therapy), Influenza, Human (virology), Microbial Sensitivity Tests, Pyrazines (pharmacology), Swine, Viral Plaque Assay, Virus Replication (drug effects).
- MESH :
- chemical , pharmacology : Amides, Antiviral Agents, Pyrazines.
- drug effects : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H2N2 Subtype, Influenza A Virus, H5N1 Subtype, Influenza A virus, Influenza B virus, Virus Replication.
- drug therapy : Influenza, Human.
- physiology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H2N2 Subtype, Influenza A Virus, H5N1 Subtype, Influenza A virus, Influenza B virus.
- virology : Influenza, Human.
- Animals, Cell Line, Dogs, Drug Resistance, Viral, Humans, In Vitro Techniques, Microbial Sensitivity Tests, Swine, Viral Plaque Assay.
Abstract
Favipiravir (T-705) has previously been shown to have a potent antiviral effect against influenza virus and some other RNA viruses in both cell culture and in animal models. Currently, favipiravir is undergoing clinical evaluation for the treatment of influenza A and B virus infections. In this study, favipiravir was evaluated in vitro for its ability to inhibit the replication of a representative panel of seasonal influenza viruses, the 2009 A(H1N1) strains, and animal viruses with pandemic (pdm) potential (swine triple reassortants, H2N2, H4N2, avian H7N2, and avian H5N1), including viruses which are resistant to the currently licensed anti-influenza drugs. All viruses were tested in a plaque reduction assay with MDCK cells, and a subset was also tested in both yield reduction and focus inhibition (FI) assays. For the majority of viruses tested, favipiravir significantly inhibited plaque formation at 3.2 muM (0.5 microg/ml) (50% effective concentrations [EC(50)s] of 0.19 to 22.48 muM and 0.03 to 3.53 microg/ml), and for all viruses, with the exception of a single dually resistant 2009 A(H1N1) virus, complete inhibition of plaque formation was seen at 3.2 muM (0.5 microg/ml). Due to the 2009 pandemic and increased drug resistance in circulating seasonal influenza viruses, there is an urgent need for new drugs which target influenza. This study demonstrates that favipiravir inhibits in vitro replication of a wide range of influenza viruses, including those resistant to currently available drugs.
DOI: 10.1128/AAC.01739-09
PubMed: 20350949
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000204
- to stream PubMed, to step Curation: 000204
- to stream PubMed, to step Checkpoint: 000183
- to stream Ncbi, to step Merge: 000510
- to stream Ncbi, to step Curation: 000510
- to stream Ncbi, to step Checkpoint: 000510
- to stream Main, to step Merge: 000E74
- to stream Main, to step Curation: 000E68
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.</title><author><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name><affiliation wicri:level="1"><nlm:affiliation>Virus Surveillance and Diagnosis Branch, Influenza Division, National Center of Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Virus Surveillance and Diagnosis Branch, Influenza Division, National Center of Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018</wicri:regionArea><wicri:noRegion>GA 30329-4018</wicri:noRegion></affiliation></author><author><name sortKey="Mishin, Vasiliy P" sort="Mishin, Vasiliy P" uniqKey="Mishin V" first="Vasiliy P" last="Mishin">Vasiliy P. Mishin</name></author><author><name sortKey="Deyde, Varough M" sort="Deyde, Varough M" uniqKey="Deyde V" first="Varough M" last="Deyde">Varough M. Deyde</name></author><author><name sortKey="Furuta, Yousuke" sort="Furuta, Yousuke" uniqKey="Furuta Y" first="Yousuke" last="Furuta">Yousuke Furuta</name></author><author><name sortKey="Klimov, Alexander I" sort="Klimov, Alexander I" uniqKey="Klimov A" first="Alexander I" last="Klimov">Alexander I. Klimov</name></author><author><name sortKey="Gubareva, Larisa V" sort="Gubareva, Larisa V" uniqKey="Gubareva L" first="Larisa V" last="Gubareva">Larisa V. Gubareva</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20350949</idno><idno type="pmid">20350949</idno><idno type="doi">10.1128/AAC.01739-09</idno><idno type="wicri:Area/PubMed/Corpus">000204</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000204</idno><idno type="wicri:Area/PubMed/Curation">000204</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000204</idno><idno type="wicri:Area/PubMed/Checkpoint">000183</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000183</idno><idno type="wicri:Area/Ncbi/Merge">000510</idno><idno type="wicri:Area/Ncbi/Curation">000510</idno><idno type="wicri:Area/Ncbi/Checkpoint">000510</idno><idno type="wicri:Area/Main/Merge">000E74</idno><idno type="wicri:Area/Main/Curation">000E68</idno><idno type="wicri:Area/Main/Exploration">000E68</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.</title><author><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name><affiliation wicri:level="1"><nlm:affiliation>Virus Surveillance and Diagnosis Branch, Influenza Division, National Center of Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Virus Surveillance and Diagnosis Branch, Influenza Division, National Center of Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018</wicri:regionArea><wicri:noRegion>GA 30329-4018</wicri:noRegion></affiliation></author><author><name sortKey="Mishin, Vasiliy P" sort="Mishin, Vasiliy P" uniqKey="Mishin V" first="Vasiliy P" last="Mishin">Vasiliy P. Mishin</name></author><author><name sortKey="Deyde, Varough M" sort="Deyde, Varough M" uniqKey="Deyde V" first="Varough M" last="Deyde">Varough M. Deyde</name></author><author><name sortKey="Furuta, Yousuke" sort="Furuta, Yousuke" uniqKey="Furuta Y" first="Yousuke" last="Furuta">Yousuke Furuta</name></author><author><name sortKey="Klimov, Alexander I" sort="Klimov, Alexander I" uniqKey="Klimov A" first="Alexander I" last="Klimov">Alexander I. Klimov</name></author><author><name sortKey="Gubareva, Larisa V" sort="Gubareva, Larisa V" uniqKey="Gubareva L" first="Larisa V" last="Gubareva">Larisa V. Gubareva</name></author></analytic><series><title level="j">Antimicrobial agents and chemotherapy</title><idno type="eISSN">1098-6596</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amides (pharmacology)</term><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Cell Line</term><term>Dogs</term><term>Drug Resistance, Viral</term><term>Humans</term><term>In Vitro Techniques</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza A Virus, H1N1 Subtype (physiology)</term><term>Influenza A Virus, H2N2 Subtype (drug effects)</term><term>Influenza A Virus, H2N2 Subtype (physiology)</term><term>Influenza A Virus, H5N1 Subtype (drug effects)</term><term>Influenza A Virus, H5N1 Subtype (physiology)</term><term>Influenza A virus (drug effects)</term><term>Influenza A virus (physiology)</term><term>Influenza B virus (drug effects)</term><term>Influenza B virus (physiology)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (virology)</term><term>Microbial Sensitivity Tests</term><term>Pyrazines (pharmacology)</term><term>Swine</term><term>Viral Plaque Assay</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Amides (pharmacologie)</term><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Chiens</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Lignée cellulaire</term><term>Méthode des plages virales</term><term>Pyrazines (pharmacologie)</term><term>Réplication virale ()</term><term>Résistance virale aux médicaments</term><term>Sous-type H1N1 du virus de la grippe A ()</term><term>Sous-type H1N1 du virus de la grippe A (physiologie)</term><term>Sous-type H2N2 du virus de la grippe A ()</term><term>Sous-type H2N2 du virus de la grippe A (physiologie)</term><term>Sous-type H5N1 du virus de la grippe A ()</term><term>Sous-type H5N1 du virus de la grippe A (physiologie)</term><term>Suidae</term><term>Techniques in vitro</term><term>Tests de sensibilité microbienne</term><term>Virus de la grippe A ()</term><term>Virus de la grippe A (physiologie)</term><term>Virus influenza B ()</term><term>Virus influenza B (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amides</term><term>Antiviral Agents</term><term>Pyrazines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H2N2 Subtype</term><term>Influenza A Virus, H5N1 Subtype</term><term>Influenza A virus</term><term>Influenza B virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Amides</term><term>Antiviraux</term><term>Pyrazines</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H2N2 du virus de la grippe A</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H2N2 Subtype</term><term>Influenza A Virus, H5N1 Subtype</term><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Dogs</term><term>Drug Resistance, Viral</term><term>Humans</term><term>In Vitro Techniques</term><term>Microbial Sensitivity Tests</term><term>Swine</term><term>Viral Plaque Assay</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Chiens</term><term>Humains</term><term>Lignée cellulaire</term><term>Méthode des plages virales</term><term>Réplication virale</term><term>Résistance virale aux médicaments</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H2N2 du virus de la grippe A</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Suidae</term><term>Techniques in vitro</term><term>Tests de sensibilité microbienne</term><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Favipiravir (T-705) has previously been shown to have a potent antiviral effect against influenza virus and some other RNA viruses in both cell culture and in animal models. Currently, favipiravir is undergoing clinical evaluation for the treatment of influenza A and B virus infections. In this study, favipiravir was evaluated in vitro for its ability to inhibit the replication of a representative panel of seasonal influenza viruses, the 2009 A(H1N1) strains, and animal viruses with pandemic (pdm) potential (swine triple reassortants, H2N2, H4N2, avian H7N2, and avian H5N1), including viruses which are resistant to the currently licensed anti-influenza drugs. All viruses were tested in a plaque reduction assay with MDCK cells, and a subset was also tested in both yield reduction and focus inhibition (FI) assays. For the majority of viruses tested, favipiravir significantly inhibited plaque formation at 3.2 muM (0.5 microg/ml) (50% effective concentrations [EC(50)s] of 0.19 to 22.48 muM and 0.03 to 3.53 microg/ml), and for all viruses, with the exception of a single dually resistant 2009 A(H1N1) virus, complete inhibition of plaque formation was seen at 3.2 muM (0.5 microg/ml). Due to the 2009 pandemic and increased drug resistance in circulating seasonal influenza viruses, there is an urgent need for new drugs which target influenza. This study demonstrates that favipiravir inhibits in vitro replication of a wide range of influenza viruses, including those resistant to currently available drugs.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Deyde, Varough M" sort="Deyde, Varough M" uniqKey="Deyde V" first="Varough M" last="Deyde">Varough M. Deyde</name><name sortKey="Furuta, Yousuke" sort="Furuta, Yousuke" uniqKey="Furuta Y" first="Yousuke" last="Furuta">Yousuke Furuta</name><name sortKey="Gubareva, Larisa V" sort="Gubareva, Larisa V" uniqKey="Gubareva L" first="Larisa V" last="Gubareva">Larisa V. Gubareva</name><name sortKey="Klimov, Alexander I" sort="Klimov, Alexander I" uniqKey="Klimov A" first="Alexander I" last="Klimov">Alexander I. Klimov</name><name sortKey="Mishin, Vasiliy P" sort="Mishin, Vasiliy P" uniqKey="Mishin V" first="Vasiliy P" last="Mishin">Vasiliy P. Mishin</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20350949
|texte= In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20350949" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |